TTNP - Titan Pharmaceuticals Inc Stock Price, Fair Value and News

$4.61

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TTNP Price Action

Last 7 days

13.8%

Last 30 days

22.2%

Last 90 days

10.1%

Trailing 12 Months

-9.1%

TTNP RSI Chart

TTNP Valuation

Market Cap

6.1M

Price/Earnings (Trailing)

-2.19

Price/Sales (Trailing)

36.15

Price/Free Cashflow

-2.23

TTNP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TTNP Fundamentals

TTNP Revenue

Revenue (TTM)

184.0K

TTNP Earnings

Earnings (TTM)

-2.8M

Earnings Growth (Yr)

67.08%

Earnings Growth (Qtr)

-22.38%

TTNP Profitability

Return on Equity

-100.61%

Return on Assets

-91.94%

Free Cashflow Yield

-44.78%

TTNP Investor Care

Shares Dilution (1Y)

45.50%

Diluted EPS (TTM)

-2.96

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	463.5K	396.5K	304.5K	184.0K
2022	1.0M	741.0K	572.0K	557.5K
2021	4.4M	3.6M	2.8M	1.5M
2020	2.8M	3.5M	3.6M	4.8M
2019	5.5M	4.3M	3.6M	2.6M
2018	1.2M	3.8M	4.8M	6.6M
2017	11.4M	7.6M	3.9M	215.0K
2016	0	15.8M	15.0M	15.1M
2015	3.6M	3.5M	2.6M	1.7M
2014	6.2M	4.9M	3.6M	3.6M
2013	11.0M	11.9M	12.8M	10.5M
2012	4.4M	5.1M	5.3M	7.1M
2011	8.9M	6.5M	5.3M	4.1M
2010	0	0	0	10.1M
2009	0	0	0	0
2008	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

CEO	Mr. David Elliot Lazar
WEBSITE	titanpharm.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	4

Titan Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Titan Pharmaceuticals Inc? What does TTNP stand for in stocks?

TTNP is the stock ticker symbol of Titan Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Titan Pharmaceuticals Inc (TTNP)?

As of Thu Oct 02 2025, market cap of Titan Pharmaceuticals Inc is 6.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TTNP stock?

You can check TTNP's fair value in chart for subscribers.

Is Titan Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether TTNP is over valued or under valued. Whether Titan Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Titan Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TTNP.

What is Titan Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Oct 02 2025, TTNP's PE ratio (Price to Earnings) is -2.19 and Price to Sales (PS) ratio is 36.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TTNP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Titan Pharmaceuticals Inc's stock?

In the past 10 years, Titan Pharmaceuticals Inc has provided -0.55 (multiply by 100 for percentage) rate of return.